<DOC>
	<DOCNO>NCT00949624</DOCNO>
	<brief_summary>A5301005 phase 1 study patient solid tumor test safety tolerability add target agent standard chemotherapy . CP-868,596 platelet-derived growth factor receptor inhibitor ( PDGFR ) AG-13736 vascular endothelial growth factor receptor inhibitor ( VEGFR ) . This study test use docetaxel ( standard chemotherapy ) either CP-868,596 combination CP-868,596 AG-13736 .</brief_summary>
	<brief_title>CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Be â‰¥18 year old histologically cytologically confirm advanced solid tumor refractory/resistant currently available therapy standard therapy . Patients primary brain tumor eligible . Have least one site measurable disease . Received chemotherapy ( include target agent erlotinib ) , radiotherapy , immunotherapy investigational therapy within 3 week study entry ( within 6 week previous treatment nitrosoureas mitomycin C ) . Received tamoxifen within 4 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>PDGFr Inhibition ;</keyword>
	<keyword>VEGFr inhibition ;</keyword>
	<keyword>target therapy</keyword>
</DOC>